Last reviewed · How we verify
Jilin Maifeng
Jilin Maifeng is a Biologic drug developed by Jiangsu Province Centers for Disease Control and Prevention. It is currently in Phase 3 development for Immune support and respiratory health (Phase 3 indication not fully specified in available data).
Jilin Maifeng is a traditional Chinese medicine formulation designed to support immune function and respiratory health.
Jilin Maifeng is a traditional Chinese medicine formulation designed to support immune function and respiratory health. Used for Immune support and respiratory health (Phase 3 indication not fully specified in available data).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Jilin Maifeng |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The drug is a herbal combination product developed by Jiangsu Province Centers for Disease Control and Prevention, intended to enhance immune response and support respiratory tract function. As a traditional Chinese medicine preparation, it likely works through multiple bioactive compounds that modulate immune pathways and promote overall wellness.
Approved indications
- Immune support and respiratory health (Phase 3 indication not fully specified in available data)
Common side effects
Key clinical trials
- A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jilin Maifeng CI brief — competitive landscape report
- Jilin Maifeng updates RSS · CI watch RSS
- Jiangsu Province Centers for Disease Control and Prevention portfolio CI
Frequently asked questions about Jilin Maifeng
What is Jilin Maifeng?
How does Jilin Maifeng work?
What is Jilin Maifeng used for?
Who makes Jilin Maifeng?
What development phase is Jilin Maifeng in?
Related
- Manufacturer: Jiangsu Province Centers for Disease Control and Prevention — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Immune support and respiratory health (Phase 3 indication not fully specified in available data)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing